Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lefrere, F
Right arrow Articles by Hermine, O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lefrere, F
Right arrow Articles by Hermine, O
Haematologica, Vol 89, Issue 10, 1275-1276
Copyright © 2004 by Ferrata Storti Foundation

Clinical Trial

Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study

F Lefrere, A Delmer, V Levy, R Delarue, B Varet, and O Hermine

This study is a long-term follow-up analysis evaluating clinical outcome of patients with mantle-cell lymphoma treated by the sequential CHOP and DHAP chemotherapy followed by autografting. The median overall survival of 81 months (95% CI, 66-not reached) and the median event free survival of 51 months (95% CI, 43-not reached) confirm the improvement in outcome obtained by such protocol.


This article has been cited by other articles:


Home page
 JCOHome page
A. Krishnan, A. Nademanee, H. C. Fung, A. A. Raubitschek, A. Molina, D. Yamauchi, R. Rodriguez, R. T. Spielberger, P. Falk, J. M. Palmer, et al.
Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol., January 1, 2008; 26(1): 90 - 95.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica, January 1, 2007; 92(1): 42 - 49.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.